Skip to main content
OpenTrials
Completed

NCT Number: NCT07102732

Modified New Mobility Score - Turkish Version

The goal of this validation and reliability study is to translate the modified version of the New Mobility Score (NMS) into Turkish (NMS-TR), culturally adapt it, and examine its psychometric properties in elderly individuals (aged 65 years and older) with hip fractures.

The main questions it aims to answer are:

1. Is the New Mobility Score a valid and reliable measurement tool for assessing mobility in Turkish individuals with hip fractures? 2. Is the New Mobility Score not a valid and reliable measurement tool in this population?

There is no comparison group in this study.

Participants will:

Provide demographic and clinical information. Undergo cognitive assessment using the Mini-Mental State Examination (MMSE). Be evaluated for comorbidity burden using the Charlson Comorbidity Index (CCI). Have their ambulatory function assessed with the Cumulative Ambulation Score (CAS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fatih Sultan Mehmet Eğitim ve Araştırma Hastanesi

Istanbul, Ataşehir, 34752, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 65 years and older
  • postoperative hip fracture who were admitted to the Orthopedics and Traumatology Department of Fatih Sultan Mehmet Training and Research Hospital

Exclusion criteria

  • under the age of 65
  • Without a hip fracture
  • Not being a voluntary participant

Treatment and study plan

Primary outcomes

  1. modified The New Mobility Score

    Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.

    The NMS requires a self-report on the ability to complete walking tasks in different settings, including indoor walking (e.g., within a house), outdoor walking, and walking during shopping. Each item is scored on a scale from 0 to 3 based on the individual's self-reported ability: a score of 0 indicates the individual was unable to complete the task, a score of 1 indicates the individual required assistance from another person to complete the task, a score of 2 indicates the individual completed the task with the aid of a walking aid, and a score of 3 indicates the individual completed the task independently without any walking assistance.

  2. Cumulative Ambulation Score

    Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.

    The Cumulative Ambulation Score assesses four distinct activities (getting out of bed, sitting, and walking) using a three-point ordinal scale ranging from 0 to 2. A score of 0 indicates that the individual is unable to perform the activity despite human assistance and verbal cues; a score of 1 signifies that the activity can be performed with human assistance and/or verbal prompting from one or more individuals; and a score of 2 denotes the ability to perform the activity safely without human assistance or verbal prompting, although the use of a walking aid is permitted. The total score ranges from 0 to 6.

Secondary outcomes

  1. Mini-Mental State Examination

    Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.

    The total score of this test ranges from 0 to 30, with lower scores indicating more pronounced cognitive impairment. In the literature, a cut-off score of 24 is commonly accepted, with scores of 24 or below suggesting a risk of cognitive impairment.

  2. The Charlson Comorbidity Index

    Time frame: From enrollment, all measurements were repeated within 2 to 7 days following the initial assessment to evaluate test-retest reliability.

    The Charlson Comorbidity Index (CCI) is a common tool used to estimate patients' long-term mortality risk. This index plays an important role in assessing health outcomes by measuring the burden of comorbidities that patients have.

Sponsors and collaborators

Lead sponsor

Istanbul Rumeli University

Other

Collaborators

  • Fatih Sultan Mehmet Training and Research Hospital
  • Istanbul University - Cerrahpasa

Registry information

Official study title

VALIDITY AND RELIABILITY OF THE TURKISH VERSION OF THE MODIFIED NEW MOBILITY SCORE

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 5, 2025
Registry last updated
Dec 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.